Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma

作者：Ikko Tomisaki, Mirii Harada, Akinori Minato, Yujiro Nagata, Rieko Kimuro, Katsuyoshi Higashijima, Kenichi Harada, Naohiro Fujimoto · 发表于：Anticancer Research · 年份：2022 · DOI：10.21873/anticanres.15638 · 被引用次数：21 · 研究领域：Cancer Immunotherapy and Biomarkers、ATP Synthase and ATPases Research、Esophageal Cancer Research and Treatment

BACKGROUND/AIM: This study aimed to clarify the impact of proton pump inhibitors (PPIs) on oncological outcomes in patients who received pembrolizumab for advanced urothelial carcinoma (UC). PATIENTS AND METHODS: Forty advanced UC patients treated with pembrolizumab were retrospectively reviewed and divided into two groups (PPI: 15 patients; without PPI: 25 patients). Tumor response and survival were compared between these groups. The factors associated with survival were also investigated. RESULTS: The objective response rate was significantly lower in the group with PPIs compared with the group without PPIs. Both progression-free survival (PFS) and overall survival (OS) were significantly shorter in the group with PPIs than in the group without PPIs. The use of PPIs was a significant predictor of poor PFS and OS in multivariate analysis. CONCLUSION: The use of PPIs was negatively associated with tumor response and survival in patients with advanced UC treated with pembrolizumab.